Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy.

ABSTRACT:

Background

Patients with cancer are at increased risk of drug-drug interactions (DDI), which can increase treatment toxicity or decrease efficacy. It is especially important to thoroughly screen DDI in oncology clinical trial subjects to ensure trial subject safety and data accuracy. This study determined the prevalence of potential DDI involving oral anti-cancer trial agents in subjects enrolled in two SWOG clinical trials.

Methods

Completed SWOG clinical trials of commercially available agents with possible DDI that had complete concomitant medication information available at enrollment were included. Screening for DDI was conducted through three methods: protocol-guided screening, Lexicomp® screening, and pharmacist determination of clinical relevance. Descriptive statist

SUBMITTER: Marcath LA 

PROVIDER: S-EPMC7995697 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature